l-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases

Maddalena Napolitano, Barbara Picconi, Diego Centonze, Giorgio Bernardi, Paolo Calabresi, Alberto Gulino

Research output: Contribution to journalArticlepeer-review


The dopamine (DA) precursor l-DOPA remains the most common treatment for Parkinson's disease (PD). However, long-term treatment with l-DOPA induces dyskinesia and motor disabilities in PD patients, indicating that this pharmacological agent is unable to fully compensate for the effects of DA denervation when used chronically. In this study, we examined the effect 6-hydroxydopamine (6-OHDA)-induced DA denervation of the striatum followed by either acute or chronic treatment with l-DOPA on gene expression of critical regulators of glutamate synaptic transmission. We found that administration of l-DOPA in rats with unilateral DA denervation resulted in a progressive increase of contraversive circling behavior and modulated the expression of Src, Lyn and PKC kinases. In particular, acute (3 days) and chronic (21 days) l-DOPA treatment were differentially able to rescue the effects of DA lesion, since only the acute treatment with l-DOPA corrected the decrease in Src, Lyn and PKC kinase expression induced by 6-OHDA lesion. Also, the reduced phosphorylation level of NR1 receptor subunit induced by 6-OHDA was only partially reversed by chronic l-DOPA treatment.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalNeuroscience Letters
Issue number3
Publication statusPublished - May 8 2006


  • 6-Hydroxydopamine
  • Dopamine
  • Glutamate
  • Lyn and Src kinases
  • Protein kinase C

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'l-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases'. Together they form a unique fingerprint.

Cite this